Sana Biotechnology ( NASDAQ: SANA) was upgraded to Market Outperform from Market Perform at Citizens as the research broker ...

Fintel reports that on March 18, 2025, Citizens Capital Markets upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) ...

Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Sana Biotechnology in a research report issued to clients and investors on Tuesday, March 18th. HC Wainwright analyst E. Bodnar ...

Late last year, the chief leasing officer for Kilroy Realty Corp. saw more biotech companies showing interest in the second ...

Citizens JMP upgraded Sana Biotechnology (SANA) to Outperform from Market Perform with a $5 price target The firm cites its cash per share and ...

Fintel reports that on March 14, 2025, Jefferies initiated coverage of Sana Biotechnology (NasdaqGS:SANA) with a Buy ...

In a significant move announced in late 2024, Sana Biotechnology has pivoted its strategy to focus primarily on its Type 1 Diabetes (T1D) and Autoimmune Disease (AID) programs. This decision led ...

Sana Biotechnology (NASDAQ:SANA – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a ...

Reports cash equivalents, and marketable securities as of December 31, were $152.5M compared to $205.2M as of December 31, 2023. The decrease ...

In a significant move announced in late 2024, Sana Biotechnology has pivoted its strategy to focus primarily on its Type 1 Diabetes (T1D) and Autoimmune Disease (AID) programs. This decision led to ...